Walsh M R, Dunckley H G, Sinclair J M, Schiff A A
Curr Med Res Opin. 1976;4(5):340-5. doi: 10.1185/03007997609109326.
In order to test the validity of the concept of anxiety states masking an underlying depressive illness, patients clinically diagnosed as suffering from anxiety or tension states were treated on a random double-blind basis for 4 weeks with either a pure anxiolytic, lorazepam, or an anxiolytic/antidepressant preparation, fluphenazine with nortriptyline. Patients' self-ratings were very similar to the physicians' ratings which showed that fluphenazine/nortriptyline was associated with significantly greater overall improvement(p less than 0.01), as well as significantly greater improvements in the group of symptoms specifically related to depression(p less than 0.05). These results suggest that a depressive element is present in an appreciable proportion of patients presenting with apparent anxiety states, and antidepressant as well as anxiolytic treatment is required. Patients selected on the basis that they had improved satisfactorily at the end of the 4-weeks' treatment were followed up for a further 3 months without medication, and the relapse rate was 24%, irrespective of previous treatment. More of the patients treated with lorazepam had to be excluded from the follow-up because of failure to improve, and these probably represented the proportion (19%) of this population with an appreciable depressive element to their illness.
为了检验焦虑状态掩盖潜在抑郁性疾病这一概念的有效性,临床上被诊断为患有焦虑或紧张状态的患者被随机双盲治疗4周,治疗药物要么是单纯的抗焦虑药劳拉西泮,要么是一种抗焦虑/抗抑郁制剂,即氟奋乃静与去甲替林。患者的自我评分与医生的评分非常相似,结果显示氟奋乃静/去甲替林与整体改善显著更大相关(p小于0.01),以及与抑郁特别相关的症状组改善也显著更大(p小于0.05)。这些结果表明,在表现出明显焦虑状态的患者中,相当一部分存在抑郁成分,需要抗抑郁以及抗焦虑治疗。在4周治疗结束时选择那些改善情况令人满意的患者,在不服药的情况下再随访3个月,复发率为24%,与之前的治疗无关。更多接受劳拉西泮治疗的患者因未改善而被排除在随访之外,这些患者可能代表了该人群中病情存在相当抑郁成分的比例(19%)。